Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630565 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00630565 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 12 participants.
The verdict
NCT00630565, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood. The stem cells are collected from the patient's blood and stored. Chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This clinical trial is studying how well an autologous stem cell transplant works in treating patients with acute myeloid leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG etoposide
- DRUG busulfan
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-07-26 |
| Est. Completion | 2022-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630565
The ClinicalTrials.gov registry entry for NCT00630565 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00630565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630565 about?
NCT00630565 is a clinical study titled "Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood. The stem cells are collected from the patient's blood and stored. Chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The ...
What is the current status of trial NCT00630565?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-07-26. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT00630565?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), etoposide (DRUG), busulfan (DRUG), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00630565?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.